iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

iBio, Inc.NASDAQ: IBIO

Operating Margin · Q4 FY2026 · quarter ended Jun 2026

Operating margin not reported for Q4 FY2026

Context

  • Operating margin widened in 1 of the last 2 fiscal years.
  • FY2026 was the lowest level in the 3 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of -4477.6% for the fiscal year ending Jun 2027, up from -35141.0% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearJun 2026
-35141.0%-30490.5 pp YoY
LTMJun 2026
-35141.0%-30490.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-36489.7 pp—
1 year-30490.5 pp+30663.4 pp+61153.9 pp
3 years—+15987.8 pp—
5 years-320226.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2026
-35141.0%
Year-over-year change
-30490.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 operating margin of -35141.0% is the lowest of the 2 companies compared; the peer median is -3278.2%.
  • Its year-over-year change of -30490.5 pp is the lowest of 2, against a peer median of +2662.7 pp.
IBIO Competitors Peer median
Operating Margin for IBIO and competitors
Company Period LTM level YoY 3-year change
RLYBRallybio CorporationLTM Mar 2026-3278.2% +2662.7 pp—
IBIOiBio, Inc.LTM Jun 2026-35141.0% -30490.5 pp—
ANTXAN2 Therapeutics, Inc.FY2025— ——
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding IBIO) -3278.2%+2662.7 pp—

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.88M0225K400K100K
Cost of Revenue3.79M0000
Gross Profit(1.91M)0225K400K100K
Gross Margin-101.2%—100.0%100.0%100.0%
Research & Development9.83M10.33M5.19M8.31M19.64M
Selling, General & Admin17.96M18.45M11.67M10.69M10.6M
Operating Expenses27.79M29.34M16.86M19M35.24M
Depreciation & Amortization3.79M1.38M1.25M1.13M646K
EBITDA(25.72M)(27.85M)(14.02M)(17.04M)(32.35M)
EBITDA Margin-1365.3%—-6231.6%-4259.8%-32345.0%
Operating Income(29.7M)(29.34M)(16.63M)(18.6M)(35.14M)
Operating Margin-1576.3%—-7392.9%-4650.5%-35141.0%
Interest Income177K213K363K437K2.15M
Interest Expense1.41M83K172K212K53K
Other Income / Expenses184K32K1.19M225K2.1M
Income Before Tax(29.51M)(29.31M)(15.44M)(18.38M)(33.04M)
Pre-Tax Margin-1566.5%—-6863.6%-4594.3%-33044.0%
Income Tax Expense00000
Net Income(50.39M)(65.01M)(24.91M)(18.38M)(33.04M)
Net Margin-2674.7%—-11069.8%-4594.3%-33044.0%
EPS (Basic)(2,889.06)(106.18)(6.50)(1.75)(0.32)
EPS (Diluted)(2,889.06)(106.18)(6.50)(1.75)(0.32)
Weighted Avg Shares17.44K612.25K3.83M10.5M104.06M
Weighted Avg Shares (Diluted)17.44K612.25K3.83M10.5M104.06M

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.